Fareva Acquires Former Merck API Mfg Facility

Fareva Acquires Former Merck API Mfg Facility

On September 1, 2015, FAREVA takes over the former MSD site of La Vallée in Saint-GermainLaprade nearby Le Puy en Velay (Haute-Loire), France. This acquisition adds another world-class facility to its pool of then 35 facilities in 11 countries.

La Vallée offers 30 years of experience in the manufacture of complex APIs and a highly motivated team of 130 highly qualified employees. It has state-of-the-art installations in production, quality control and environmental systems. With a total reactor capacity of 128,000 liters in large and small scale workshops it nearly doubles FAREVA's API capacity from the existing facilities in Feucht (Excella/Germany), Val de Reuil (Valdepharm/France) and Romainville (FAREVA Romainville/France). Following its strategy of investment into niche technologies, FAREVA is going to further strengthen the capabilities of the site by investing around 25 million Euros into an OEB 4 high-containment facility. Two separated compartments with 4,000 liter reactors and high-containment dryers will be operational mid-2017. In addition a hastelloy flow train for cryogenic chemistry at 2 to 10 cubic meter scale is also under development. Thanks to space available in the plant, additional production facilities can be added to satisfy potential customers.

FAREVA La Vallée was built in 1985 and has an excellent track record in regulatory inspections by all major authorities. The site manufactures large and small volume APIs for highly regulated markets. Additionally, the safety culture on site is outstanding. There has never been an environmental incident in the 30 year history of the site, and no lost time accident for the last two years.

FAREVA is a global leader in custom-manufacturing for the pharmaceutical, cosmetics and household chemicals industries with more than 1,000 customers worldwide and a global turnover of more than 1.3 billion Euros in 2014. 

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.